ArticleaBIOTECH2026
Motif-Hi-C: A motif-based framework for rapid quality control of Hi-C data.
Article in aBIOTECH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hi-C technology has become indispensable for studying three-dimensional (3D) genome organization; however, the substantial variability in existing genome analysis tools poses challenges for efficient, accurate data processing. Here, we present Motif-Hi-C, an innovative computational framework that leverages the intrinsic sequence signatures of Hi-C chimeric reads to enable rapid, reliable quality control. Through systematic benchmarking of four mainstream tools (HiC-Pro, HiCUP, Juicer, and HiCExplorer) across diverse Hi-C datasets, we identified critical trade-offs between processing speed and analytical precision. Motif-Hi-C addresses these limitations by implementing a motif-aware classification system that achieves faster processing with more valid interacting rmdup/total read pairs. Key innovations include (1) automated detection of ligation-motif signatures in raw sequencing data, (2) category-specific parallel processing pipelines, and (3) dynamic quality thresholds adapted to different experimental protocols. Validation across multiple cell types and restriction enzymes demonstrated robust performance, with particular advantages for large-scale consortium datasets. This framework establishes a new paradigm for efficient quality assessment in 3D genomics studies, seamlessly integrating with downstream chromatin interaction analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.